|  |  | SBRT | CF-EBRT | p-value |
---|---|---|---|---|---|
 |  | Through year |  |  |  |
# Evaluable patients with PSA | 26 | 37 | Â | ||
Follow-up for All 3 intervals | Â | Â | Â | Â | |
PSA measurements | Â | Â | Â | Â | |
 | Mean (range) | 1 | 3.8 (2 – 5) | 4.2 (3 – 11) |  |
 |  | 2 | 5.8 (4 – 8) | 6.6 (4 – 15) |  |
 |  | 3 | 7.6 (5 – 11) | 9.0 (6 – 21) | p = 0.03# |
Nadir PSA (ng/mL) | Â | Â | Â | Â | |
 | Median (range) | 1 | 0.81 (0.1 – 2.5) | 1.00 (0 – 8.5) |  |
 |  | 2 | 0.45 (0.1 – 1.4) | 0.86 (0 – 2.5) | p = 0.02* |
 |  | 3 | 0.25 (0.1 – 1.4) | 0.70 (0 – 2.2) | p = 0.002* |
Time to Nadir PSA (mos.) | Â | Â | Â | Â | |
 | Median (range) | 1 | 12.0 (2.7 – 15.0) | 11.5 (1.2 – 15.0) |  |
 |  | 2 | 22.1 (2.7 – 26.9) | 17.9 (1.2 – 26.9) |  |
 |  | 3 | 31.5 (2.7 – 41.6) | 27.4 (1.2 – 41.0) | p = 0.02^ |
Rate of PSA change: ng/mL/month | Â | Â | Â | ||
 | Median slope (range) | 1 | -0.08 (-0.88, 0.04) | -0.09 (-0.60, 0.06) |  |
 |  | 2 | -0.06 (-0.38, 0.004) | -0.04 (-0.65, 0.05) |  |
 |  | 3 | -0.05 (-0.19, 0.001) | -0.03 (-0.38, 0.02) |  |